Kilo Kaybı

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Not a true peptide, but a small molecule compound used in longevity and metabolic optimization protocols.

Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.

Clenbuterol is a potent, long-acting beta-2 adrenergic receptor agonist originally developed for the treatment of asthma and other respiratory conditions. It is approved as a bronchodilator in many countries throughout Europe, Latin America, and Asia, but has never been approved for human use in the United States, where it is only approved for veterinary use in horses (Ventipulmin). In the context of bodybuilding and physique sports, clenbuterol is widely used as a thermogenic agent during cutting phases to accelerate fat loss while preserving lean muscle mass. Its stimulatory effects on the sympathetic nervous system increase basal metabolic rate, core body temperature, and lipolysis. Unlike anabolic steroids, clenbuterol does not directly promote muscle growth in humans at typical doses, though animal studies have demonstrated significant anabolic effects in livestock, which led to its controversial use in meat production in some countries.

GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.

GHRP-6 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It was one of the first GHRPs developed and works by binding to the ghrelin receptor (GHS-R1a). Unlike direct HGH injections, GHRP-6 enhances the body's natural GH production while keeping negative feedback mechanisms balanced. It is known for its potent appetite-stimulating effects.

Hexarelin is one of the most potent synthetic growth hormone secretagogues available. It stimulates GH release by binding to the GHS-R1a receptor in the pituitary and hypothalamus, mimicking the action of ghrelin. Notably, Hexarelin demonstrates synergistic effects when combined with GHRH, producing GH responses greater than the arithmetic sum of either peptide alone. It also shows unique cardioprotective properties mediated through the CD36 receptor.

Human Growth Hormone (HGH/Somatropin) is a 191-amino acid polypeptide hormone FDA-approved for pediatric and adult growth hormone deficiency, HIV-associated wasting, and other conditions. It provides both direct and indirect (IGF-1 mediated) anabolic effects.

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.

Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.

KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).

Liothyronine (T3) is the biologically active form of thyroid hormone, responsible for regulating basal metabolic rate, thermogenesis, protein synthesis, and cellular energy metabolism throughout the body. Unlike levothyroxine (T4), which serves primarily as a prohormone requiring peripheral conversion by deiodinase enzymes, T3 acts directly on nuclear thyroid hormone receptors to exert its metabolic effects. It has been FDA-approved since the 1950s for the treatment of hypothyroidism, myxedema coma, and as a diagnostic agent in thyroid suppression tests. Pharmaceutical T3 is available as Cytomel (brand) and generic liothyronine sodium tablets. In performance and biohacking contexts, T3 is widely used during cutting phases to accelerate fat loss by directly upregulating metabolic rate, and by individuals seeking metabolic optimization when peripheral T4-to-T3 conversion is impaired due to caloric restriction, stress, or other factors.

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.

Oral compound activating ghrelin receptors to trigger growth hormone release while preserving natural production. Achieves superior oral bioavailability exceeding 60% with a 24-hour half-life, making it unique among GH secretagogues for its convenient once-daily oral dosing.

First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.

Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing.

Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preserving physiological pulsatile patterns. Originally FDA-approved in 1997 for pediatric GH deficiency, it was discontinued in 2008 for manufacturing reasons, not safety concerns.

Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.

Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.

Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.